LONDON, Oct. 7, 2015 /PRNewswire/ -- Smith &
Nephew (NYSE:SNN; LSE:SN), the global, medical technology business,
today announced the launch of its TRIGEN META-TAN (Trochanteric
Antegrade Nail) System at the Orthopaedic Trauma Association's
(OTA) annual meeting in San Diego.
The META-TAN System expands the clinically proven TRIGEN Nail
portfolio with a versatile design that addresses a wide range of
femoral fractures ranging from specific hip fractures to mid-shaft
fractures and fractures near the knee.
For hip fractures in patients with good bone quality, the
META-TAN System features the company's unique dual integrated screw
design which is able to gain and maintain compression of the
proximal femur. Additionally, the thinner size of the new nail may
also benefit patients with narrow femoral canals.
For mid-shaft fractures and fractures near the knee, the
variable bow of the nail provides versatile options for varying
patient anatomy, and the multi-planar screw configuration allows
for optimum fracture stability.
"High energy fractures in patients with good bone quality and
less available space often pose challenges," says Dr. Daniel Chan of Georgia Orthopaedic Trauma
Institute. "META-TAN is an excellent solution as it does not
require much bone removal with its smaller proximal body, while
offering 'recon' compression capability when desired."
Surgeons attending this week's annual OTA meeting can learn more
about the TRIGEN META-TAN System at the Smith & Nephew booth,
#502.
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 14,000 employees and a
presence in more than 100 countries. Annual sales in 2014 were more
than $4.6 billion. Smith & Nephew
is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit our
corporate website www.smith-nephew.com, follow @SmithNephewplc on
Twitter or visit SmithNephewplc on Facebook.com
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls; litigation relating to patent or other claims;
legal compliance risks and related investigative, remedial or
enforcement actions; strategic actions, including acquisitions and
dispositions, our success in performing due diligence, valuing and
integrating acquired businesses; disruption that may result from
transactions or other changes we make in our business plans or
organisation to adapt to market developments; and numerous other
matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith & Nephew has filed
with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith &
Nephew's most recent annual report on Form 20-F, for a discussion
of certain of these factors. Any forward-looking statement is based
on information available to Smith & Nephew as of the date of
the statement. All written or oral forward-looking statements
attributable to Smith & Nephew are qualified by this caution.
Smith & Nephew does not undertake any obligation to update or
revise any forward-looking statement to reflect any change in
circumstances or in Smith & Nephew's expectations.
™Trademark of Smith & Nephew. Registered US Patent
and Trademark Office.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-trigen-meta-tan-nail-expands-smith--nephews-femoral-nail-portfolio-300155458.html
SOURCE Smith & Nephew